LBH589 (Panobinostat) for the Treatment of Myelofibrosis

NCT01298934 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Primary Myelofibrosis
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
Post-Essential Thrombocythemia Related Myelofibrosis

Interventions

DRUG: LBH589

Sponsor

Ronald Hoffman

Collaborators

[object Object]